Your browser doesn't support javascript.
loading
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
van Waalwijk van Doorn-Khosrovani, S B; Pisters-van Roy, A; van Saase, L; van der Graaff, M; Gijzen, J; Sleijfer, S; Hoes, L R; van Berge Henegouwen, J M; van der Wijngaart, H; van der Velden, D L; van Werkhoven, E; Retel, V P; van Harten, W H; Huitema, A D R; Timmers, L; Gelderblom, H; Verheul, H M W; Voest, E E.
Afiliação
  • van Waalwijk van Doorn-Khosrovani SB; CZ Health Insurance, Tilburg.
  • Pisters-van Roy A; CZ Health Insurance, Tilburg.
  • van Saase L; National Health Care Institute (Zorginstituut Nederland), Diemen.
  • van der Graaff M; National Health Care Institute (Zorginstituut Nederland), Diemen.
  • Gijzen J; CZ Health Insurance, Tilburg.
  • Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Center for Personalised Cancer Treatment (CPCT).
  • Hoes LR; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam.
  • van Berge Henegouwen JM; Division of Medical Oncology, Leiden University Medical Center, Leiden.
  • van der Wijngaart H; Division of Medical Oncology, Amsterdam University Medical Center, Cancer Center Amsterdam, Amsterdam.
  • van der Velden DL; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam.
  • van Werkhoven E; Department of Biometrics, Netherlands Cancer Institute, Amsterdam.
  • Retel VP; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam; Department of Health Technology and Services Research, University of Twente, Enschede.
  • van Harten WH; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam; Department of Health Technology and Services Research, University of Twente, Enschede; Rijnstate Hospital, Arnhem.
  • Huitema ADR; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam; Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Timmers L; National Health Care Institute (Zorginstituut Nederland), Diemen.
  • Gelderblom H; Division of Medical Oncology, Leiden University Medical Center, Leiden.
  • Verheul HMW; Division of Medical Oncology, Leiden University Medical Center, Leiden.
  • Voest EE; Center for Personalised Cancer Treatment (CPCT); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam. Electronic address: e.voest@nki.nl.
Ann Oncol ; 30(5): 663-665, 2019 05 01.
Article em En | MEDLINE | ID: mdl-31038154
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 Problema de saúde: 2_cobertura_universal Assunto principal: Mecanismo de Reembolso / Biomarcadores Tumorais / Medicina de Precisão / Neoplasias Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 Problema de saúde: 2_cobertura_universal Assunto principal: Mecanismo de Reembolso / Biomarcadores Tumorais / Medicina de Precisão / Neoplasias Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article